MedinCell: US Pharma Development expert Richard Malamut, MD becomes Chief Medical Officer 

May 9, 2022

• Dr. Rick Malamut is an expert in regulatory processes and drug development 
• He oversaw the early clinical strategy of mdc-IRM at Teva (2013-2016) 
• He is a former member of MedinCell’s Medical Advisory Board and MedinCell’s board of directors’ observer 
• He joins MedinCell as part of the newly created US subsidiary 

 “After working as an active member of the Medical Advisory Board of MedinCell, I am delighted to be joining full time the company as a CMO at a time when its first product is in the final stage of the FDA approval process. I look forward to contribute to the success of the other programs in MedinCell’s pipeline. 
MedinCell’s breakthrough technology allows for significant clinical improvements to existing medications and will provide meaningful benefits to patients across a broad range of therapeutic indications,” said Dr Malamut. 

“I am truly delighted. We’ve known Richard since 2013 when he was at Teva. Richard is going to bring MedinCell his deep knowledge of U.S. regulatory processes and clinical development, as well as be instrumental in evaluating new opportunities. He is an expert in both central nervous system and pain, where we are very active,” said Christophe Douat, CEO of MedinCell. His input will be major for the next stage of the company as more and more of our programs have reached regulatory stage, and more to come, with most of clinical development activities conducted in the U.S.” 

About Dr. Richard Malamut 
Before joining MedinCell as Chief Medical Officer, Dr. Richard Malamut was Chief Medical Officer and Executive Vice President at Collegium Pharmaceuticals and Chairman of MedinCell Medical Advisory Board. He also served as Chief Medical Officer for both Braeburn Pharmaceuticals and Avanir Pharmaceuticals. Previously, from 2013 to 2016, he was the Senior Vice President of Global Clinical Development for Pain, Neuropsychiatry, Oncology, and New Therapeutic Entities at Teva Pharmaceuticals. Prior to that, he had multiple roles with increasing responsibilities at Bristol-Myers and AstraZeneca focused on early clinical development and translational medicine. 

Dr. Malamut earned his medical degree from Hahnemann University in Philadelphia and completed both a residency in Neurology and a fellowship in neuromuscular disease. He worked as a board-certified academic and clinical neurologist for 17 years and has more than 50 publications in the fields of pain medicine, neuromuscular disease, autonomic disease, and neurodegenerative disease. 

Session en français

Rendez-vous le mardi 12 septembre à 18h00 pour la diffusion en direct de l'Assemblée Générale mixte

English session

On Tuesday September 12 at 6:00 p.m. live of the Combined General Meeting (in French)

Êtes-vous un actionnaire de MedinCell ? / Are you a MedinCell shareholder?
Vous êtes / You are :
This field is for validation purposes and should be left unchanged.


  • This field is for validation purposes and should be left unchanged.